MDxHealth Announces Completion of Transition to Single Listing on Nasdaq
18 Dicembre 2023 - 7:00AM
NEWS RELEASE – REGULATED
INFORMATIONDECEMBER 18, 2023, 1:00 AM ET / 07:00
AM CET
MDxHealth Announces Completion of
Transition to Single Listing on Nasdaq
IRVINE, CA, and HERSTAL,
BELGIUM – December 18, 2023 – MDxHealth SA
(NASDAQ/Euronext Brussels: MDXH) (the "Company" or "mdxhealth"), a
commercial-stage precision diagnostics company, today announces the
completion of its transition to a single listing on Nasdaq.
In accordance with prior announcements made by
the Company and the corporate event notice issued by Euronext on
December 6, 2023, the last trading day of the Company's ordinary
shares (the "Shares") on the regulated market of Euronext Brussels
was December 15, 2023. Trading of the Shares on Euronext Brussels
will not resume and the Shares will, as from today, be de-listed
from Euronext and will only be listed and tradeable on Nasdaq.
Nothwistanding the above, all Shares, whether or
not repositioned to Nasdaq, will continue to be valid Shares with
full voting rights, rights to future dividends and other
distributions, etc. Furthermore, Shares that have not been
repositioned prior to December 15, 2023, the last date that Shares
were listed and tradeable on Euronext Brussels, may still be
repositioned for trading on Nasdaq at any time after today by
contacting the shareholder’s financial intermediary or
custodian.
For further information and details regarding
the transition to a single listing of Shares on Nasdaq and the
repositioning process, please visit the dedicated web page on the
Company's website (see: Proposed Transition to a Single Listing on
NASDAQ - mdxhealth).
About mdxhealth®
Mdxhealth is a commercial-stage precision
diagnostics company that provides actionable molecular information
to personalize patient diagnosis and treatment. The Company’s tests
are based on proprietary genomic, epigenetic (methylation) and
other molecular technologies and assist physicians with the
diagnosis and prognosis of urologic cancers and other urologic
diseases. The Company’s U.S. headquarters and laboratory operations
are in Irvine, California, with additional laboratory operations in
Plano, Texas. European headquarters are in Herstal, Belgium, with
laboratory operations in Nijmegen, The Netherlands. For more
information, visit mdxhealth.com and follow us on social
media
at:twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.
For more information:
mdxhealth info@mdxhealth.com |
|
LifeSci
Advisors (IR & PR)US: +1 949 271
9223ir@mdxhealth.com |
|
Forward-looking Statements
This press release contains forward-looking
statements and estimates with respect to the anticipated future
performance of MDxHealth and the market in which it operates, all
of which involve certain risks and uncertainties. These statements
are often, but are not always, made through the use of words or
phrases such as “potential,” “expect,” “will,” “goal,” “next,”
“potential,” “aim,” “explore,” “forward,” “future,” and “believes”
as well as similar expressions. Forward-looking statements
contained in this release include, but are not limited to,
statements regarding timing of the proposed transition from a dual
listing of shares on Euronext Brussels and ADSs on Nasdaq to a sole
listing of shares on Nasdaq and Share Consolidation, including
statements regarding European financial intermediaries and
custodians using their discretionary authority to reposition their
clients’ securities. Such statements and estimates are based on
assumptions and assessments of known and unknown risks,
uncertainties and other factors, which were deemed reasonable but
may not prove to be correct. Actual events are difficult to
predict, may depend upon factors that are beyond the company’s
control, and may turn out to be materially different. Examples of
forward-looking statements include, among others, statements we
make regarding expected future operating results, product
development efforts, our strategies, positioning, resources,
capabilities and expectations for future events or performance.
Important factors that could cause actual results, conditions and
events to differ materially from those indicated in the
forward-looking statements include, among others, the following:
uncertainties associated with the coronavirus (COVID-19) pandemic,
including its possible effects on our operations, and the demand
for our products; our ability to successfully and profitably market
our products; the acceptance of our products and services by
healthcare providers; the willingness of health insurance companies
and other payers to cover our products and services and adequately
reimburse us for such products and services; our ability to obtain
and maintain regulatory approvals and comply with applicable
regulations; the possibility that the anticipated benefits from our
business acquisitions like our acquisition of the Oncotype DX® GPS
prostate cancer business will not be realized in full or at all or
may take longer to realize than expected; and the amount and nature
of competition for our products and services. Other important risks
and uncertainties are described in the Risk Factors sections of our
most recent Annual Report on Form 20-F and in our other reports
filed with the Securities and Exchange Commission. MDxHealth
expressly disclaims any obligation to update any such
forward-looking statements in this release to reflect any change in
its expectations with regard thereto or any change in events,
conditions or circumstances on which any such statement is based
unless required by law or regulation. This press release does not
constitute an offer or invitation for the sale or purchase of
securities or assets of MDxHealth in any jurisdiction. No
securities of MDxHealth may be offered or sold within the United
States without registration under the U.S. Securities Act of 1933,
as amended, or in compliance with an exemption therefrom, and in
accordance with any applicable U.S. securities laws.
NOTE: The mdxhealth logo,
mdxhealth, Confirm mdx, Select mdx, Resolve mdx, Genomic Prostate
Score, GPS and Monitor mdx are trademarks or registered trademarks
of MDxHealth SA. All other trademarks and service marks are the
property of their respective owners.
Grafico Azioni MDxHealth (EU:MDXH)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni MDxHealth (EU:MDXH)
Storico
Da Giu 2023 a Giu 2024